Biotech | August 25, 2025
Boehringer and AnGes sign manufacturing agreement for HGF gene therapy product
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Subscribe To Our Newsletter & Stay Updated
